Advanced Filters
noise

friedreichs-ataxia Clinical Trials

A listing of friedreichs-ataxia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 21 clinical trials

A Study to Assess Nomlabofusp in Adolescents and Children with Friedreich's Ataxia

The goal of this clinical trial is to evaluate the safety and tolerability of nomlabofusp (CTI-1601) in adolescents and children with Friedreich's ataxia (FRDA).

2 - 17 years of age All Phase 1
V Varlli Scott

A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's Ataxia

The purpose of this study is to evaluate the safety and tolerability, and pharmacokinetics of DT-216P2 administered multiple ascending doses in patients with FA.

18 - 65 years of age All Phase 1/2

Efficacy of Stabilometric Platform to Improve Standing Balance in Patients With Friedreich's Ataxia

The primary objective is to evaluate the potential effectiveness of an individualized intensive rehabilitation intervention using the "Prokin 252" stabilometric platform in the treatment of adolescent and adult patients with Friedreich's Ataxia. The secondary objective is to assess the retention of the rehabilitation treatment effects over time. Enrolled patients will …

14 years of age All Phase N/A
N Niamh Savage, BS

Phase IA Study of AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich's Ataxia

The purpose of this study is to test the safety and preliminary efficacy of AAVrh.10hFXN to treat the cardiomyopathy associated with Friedreich's ataxia (FA). AAVrh.10hFXN is a serotype rh.10 adeno-associated virus gene transfer vector coding for Frataxin (FXN). The drug is administered intravenously. This is a phase 1, open label, …

18 - 50 years of age All Phase 1

A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About Its Safety in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old

In this study, researchers will learn more about BIIB141, also known as omaveloxolone or SKYCLARYS®. This drug has been approved, or made available for doctors to prescribe, for people with Friedrich's Ataxia (FA) who are at least 16 years old. But, it is not yet available for children and teens …

2 - 15 years of age All Phase 1
C Crystal Proud, M.D.

A Study to Learn More About the Effects and Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old

In this study, researchers will learn more about the effects and safety of BIIB141, also known as omaveloxolone or SKYCLARYS®. This drug has been approved, or made available for doctors to prescribe, for people with Friedreich's Ataxia (FA) who are at least 16 years old. But, it is not yet …

2 - 15 years of age All Phase 3
L Leonardo Boccuni, PhD

Electroencephalogram in Patients With Friedreich's Ataxia for the Study of the Structural and Functional Connectome.

Prospective, exploratory, multicenter pilot study investigating the structural and functional connectome in patients with Friedreich's Ataxia (FRDA) using high-density electroencephalogram (HD-EEG). The aim is to identify neurophysiological biomarkers and analyze the relationship between cortical connectivity, cognitive functioning, and clinical severity, particularly in response to rehabilitation treatment.

8 - 60 years of age All Phase N/A
M Manuel A Guerrero Gutierrez, MD

Indocyanine Green Fluorescence Angiography (ICG-FA) in Revisional Bariatric Surgery

This study will compare different doses of a green fluorescent product that is administered during weight loss surgery in order to observe where blood vessels are located. There is uncertainty around the optimal dose of this product for patients with obesity, so this study will aim to study if the …

18 years of age All Phase N/A
P Principal Investigator Selected by Sponsor, M.D., Ph.D.

Afatinib in Patients with Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

This research study is a phase Ib/II, single-arm, non-randomized, non-blind, multicenter study designed to determine whether Afatinib is effective and safe in patients with locoregionally unresectable and / or metastatic HNSCC with Fanconi Anemia. The main hypothesis, based on preclinical evidence, is that treatment with afatinib, an epithelial growth factor …

18 years of age All Phase 1/2
C Célia Parinot, PhD

Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study

This project is a global, multicenter, prospective, longitudinal, observational natural history study that can be used to understand the disease progression and support the development of safe and effective drugs and biological products for Friedreich ataxia.

years of age All Phase N/A

Simplify language using AI